Aliases & Classifications for Paronychia

MalaCards integrated aliases for Paronychia:

Name: Paronychia 12 74 54 43 15 17
Paronychia Inflammation 12 71
Onychia and Paronychia of Finger 12
Onychia and Paronychia of Toe 12
Fungal Nail Infection 12
Infected Nailfold 12
Onychomycosis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:13117
MeSH 43 D010304
NCIt 49 C79702
SNOMED-CT 67 71906005
ICD10 32 L03.0
UMLS 71 C0030578 C0040261

Summaries for Paronychia

Disease Ontology : 12 A nail disease characterized by often-tender bacterial or fungal hand infection or foot infection due to either bacteria or fungus (Candida albicans) where the nail and skin meet at the side or the base of a finger or toe nail. The infection can start suddenly (acute paronychia) or gradually (chronic paronychia). Puss is usually present, along with gradual thickening and browning discoloration of the nail plate.

MalaCards based summary : Paronychia, also known as paronychia inflammation, is related to papillary adenocarcinoma and neurofibromatosis, type ii. An important gene associated with Paronychia is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and HIV Life Cycle. The drugs leucovorin and Phylloquinone have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and testes, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Paronychia is a nail infection that is an often tender bacterial or fungal infection of the hand or... more...

Related Diseases for Paronychia

Diseases related to Paronychia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 256)
# Related Disease Score Top Affiliating Genes
1 papillary adenocarcinoma 30.0 KRAS HRAS ERBB2
2 neurofibromatosis, type ii 29.5 MTOR HRAS ERBB4 ERBB3 ERBB2 EGFR
3 melanoma 29.3 MTOR KRAS HRAS ERBB4 ERBB2 EGFR
4 adenocarcinoma 29.1 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
5 lung cancer susceptibility 3 28.6 MTOR MAP2K7 KRAS HRAS ERBB4 ERBB3
6 exanthem 28.6 MTOR MAP2K7 KRAS HRAS ERBB2 EGFR
7 candidal paronychia 12.4
8 neuropathy, hereditary sensory and autonomic, type iia 11.3
9 pyogenic granuloma 10.4
10 vaginal adenosarcoma 10.4 MTOR ERBB4
11 vaginal carcinosarcoma 10.4 MTOR ERBB4
12 pemphigus 10.4
13 signet ring basal cell carcinoma 10.4 KRAS HRAS
14 trachea carcinoma in situ 10.4 KRAS HRAS
15 cobblestone retinal degeneration 10.4 KRAS HRAS
16 nasal cavity adenocarcinoma 10.4 KRAS HRAS
17 ampulla of vater neoplasm 10.4 KRAS HRAS
18 descending colon cancer 10.4 KRAS HRAS
19 periampullary adenoma 10.4 KRAS HRAS
20 transverse colon cancer 10.4 KRAS HRAS
21 pemphigus vulgaris, familial 10.4
22 contact dermatitis 10.4
23 appendiceal neoplasm 10.4 KRAS HRAS
24 gallbladder benign neoplasm 10.4 KRAS HRAS
25 recurrent respiratory papillomatosis 10.4 ERBB2 EGFR
26 breast scirrhous carcinoma 10.4 ERBB2 EGFR
27 myh-associated polyposis 10.4 KRAS HRAS
28 appendix adenocarcinoma 10.4 KRAS HRAS
29 wolffian duct adenocarcinoma 10.3 KRAS HRAS
30 ascending colon cancer 10.3 KRAS HRAS
31 biliary tract benign neoplasm 10.3 KRAS HRAS
32 papillary squamous carcinoma 10.3 ERBB3 EGFR
33 tumor of exocrine pancreas 10.3 KRAS HRAS
34 breast squamous cell carcinoma 10.3 HRAS ERBB2
35 breast metaplastic carcinoma 10.3 ERBB2 EGFR
36 pancreatic acinar cell adenocarcinoma 10.3 KRAS HRAS
37 endosalpingiosis 10.3 KRAS HRAS
38 breast malignant phyllodes tumor 10.3 ERBB2 EGFR
39 kala-azar 1 10.3
40 leishmaniasis 10.3
41 core binding factor acute myeloid leukemia 10.3 KRAS HRAS
42 progesterone-receptor negative breast cancer 10.3 ERBB2 EGFR
43 submandibular gland cancer 10.3 ERBB2 EGFR
44 appendix disease 10.3 KRAS HRAS
45 adenosquamous lung carcinoma 10.3 KRAS HRAS EGFR
46 lung carcinoma in situ 10.3 KRAS HRAS EGFR
47 pulmonary adenocarcinoma in situ 10.3 KRAS HRAS EGFR
48 adenocarcinoma in situ 10.3 KRAS HRAS EGFR
49 squamous cell carcinoma 10.2
50 dermatitis 10.2

Graphical network of the top 20 diseases related to Paronychia:



Diseases related to Paronychia

Symptoms & Phenotypes for Paronychia

GenomeRNAi Phenotypes related to Paronychia according to GeneCards Suite gene sharing:

26 (show top 50) (show all 53)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.31 MTOR HRAS KRAS AURKA EGFR
2 Decreased viability GR00055-A-2 11.31 MTOR HRAS KRAS AURKA EGFR
3 Decreased viability GR00055-A-3 11.31 KRAS
4 Decreased viability GR00106-A-0 11.31 ERBB3 KRAS
5 Decreased viability GR00221-A-1 11.31 MTOR HRAS KRAS AURKA EGFR MAP2K7
6 Decreased viability GR00221-A-2 11.31 ERBB3 MAP3K8 HRAS KRAS AURKA
7 Decreased viability GR00221-A-3 11.31 MAP3K8 ERBB2 HRAS WNK1
8 Decreased viability GR00221-A-4 11.31 ERBB3 MAP3K8 MTOR ERBB2 WNK1 AURKA
9 Decreased viability GR00231-A 11.31 AURKA
10 Decreased viability GR00249-S 11.31 WNK1 AURKA MAP2K7
11 Decreased viability GR00301-A 11.31 ERBB3 MAP3K8 ERBB4 KRAS
12 Decreased viability GR00342-S-1 11.31 MAP3K8 MTOR ERBB4
13 Decreased viability GR00342-S-2 11.31 MAP3K8 MTOR
14 Decreased viability GR00342-S-3 11.31 MAP3K8
15 Decreased viability GR00381-A-1 11.31 KRAS
16 Decreased viability GR00386-A-1 11.31 WNK1
17 Decreased viability GR00402-S-2 11.31 MAP3K8 WNK1 AURKA MAP2K7
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.62 KRAS MTOR
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.62 ERBB3
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.62 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.62 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.62 ERBB3 MTOR WNK1
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.62 KRAS
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 10.62 KRAS
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.62 MTOR
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.62 KRAS
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.62 KRAS
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-196 10.62 KRAS
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-198 10.62 ERBB3
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.62 ERBB3 KRAS
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-23 10.62 KRAS
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.62 KRAS
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.62 KRAS WNK1
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.62 MTOR WNK1
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.62 KRAS
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.62 KRAS
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.62 ERBB3 KRAS MTOR WNK1
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.62 KRAS
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.62 MTOR WNK1
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-93 10.62 KRAS
41 Decreased substrate adherent cell growth GR00193-A-1 10.11 AURKA ERBB3
42 Decreased substrate adherent cell growth GR00193-A-2 10.11 AURKA EGFR ERBB3 MAP2K7 MAP3K8 MTOR
43 Decreased substrate adherent cell growth GR00193-A-3 10.11 MAP2K7 WNK1
44 Decreased cell migration GR00055-A-3 10.08 AURKA EGFR HRAS MTOR
45 Decreased cell proliferation GR00353-A 9.76 AURKA ERBB2 MTOR WNK1
46 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.73 ERBB3 ERBB4 MAP2K7 MTOR
47 Decreased viability with paclitaxel GR00179-A-1 9.65 EGFR MTOR
48 Decreased viability with paclitaxel GR00179-A-2 9.65 MTOR
49 Decreased viability with paclitaxel GR00179-A-3 9.65 EGFR MTOR
50 Reduced mammosphere formation GR00396-S 9.1 EGFR ERBB3 HRAS KRAS MAP3K8 MTOR

MGI Mouse Phenotypes related to Paronychia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 CDAN1 ERBB2 ERBB3 ERBB4 HRAS KRAS
2 cardiovascular system MP:0005385 10.16 CDAN1 EGFR ERBB2 ERBB3 ERBB4 HRAS
3 mortality/aging MP:0010768 10.1 AURKA CDAN1 EGFR ERBB2 ERBB3 ERBB4
4 embryo MP:0005380 10.09 AURKA CDAN1 EGFR ERBB2 ERBB3 ERBB4
5 growth/size/body region MP:0005378 10.07 AURKA CDAN1 EGFR ERBB2 ERBB3 HRAS
6 endocrine/exocrine gland MP:0005379 10.06 CDAN1 EGFR ERBB2 ERBB3 ERBB4 HRAS
7 muscle MP:0005369 9.8 EGFR ERBB2 ERBB3 ERBB4 KRAS MTOR
8 neoplasm MP:0002006 9.76 AURKA EGFR ERBB2 ERBB3 HRAS KRAS
9 normal MP:0002873 9.61 CDAN1 EGFR ERBB2 ERBB3 ERBB4 HRAS
10 respiratory system MP:0005388 9.17 EGFR ERBB2 ERBB3 ERBB4 HRAS KRAS

Drugs & Therapeutics for Paronychia

Drugs for Paronychia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4 58-05-9 6006 143
2
Phylloquinone Approved, Investigational Phase 4 84-80-0
3
Cetuximab Approved Phase 4 205923-56-4 56842117 2333
4
Fluorouracil Approved Phase 4 51-21-8 3385
5
Irinotecan Approved, Investigational Phase 4 97682-44-5, 100286-90-6 60838
6
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
7
Amorolfine Approved, Investigational Phase 4 78613-35-1
8
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
9
Tavaborole Approved, Investigational Phase 4 174671-46-6
10
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
11
Bifonazole Approved, Investigational Phase 4 60628-96-8 2378
12
carbamide peroxide Approved Phase 4 124-43-6
13
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
14
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
15
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
16
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
17
Efinaconazole Approved Phase 4 164650-44-6
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
19
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
20 Menaquinone Investigational Phase 4 1182-68-9
21 Dermatologic Agents Phase 4
22 Keratolytic Agents Phase 4
23 Immunoglobulins Phase 4
24 Vitamins Phase 4
25 Antibodies Phase 4
26 Vitamin B Complex Phase 4
27 Antibodies, Monoclonal Phase 4
28 Folate Phase 4
29 Vitamin K Phase 4
30 Vitamin B9 Phase 4
31 naphthoquinone Phase 4
32 Antineoplastic Agents, Immunological Phase 4
33 Vitamin K 1 Phase 4
34 Pharmaceutical Solutions Phase 4
35
Hydroxyitraconazole Phase 4
36 Antifungal Agents Phase 4
37 Anti-Infective Agents Phase 4
38 Anti-Bacterial Agents Phase 4
39 Antiprotozoal Agents Phase 4
40 Antiparasitic Agents Phase 4
41 Amebicides Phase 4
42 Antioxidants Phase 4
43 Protective Agents Phase 4
44 Liposomal amphotericin B Phase 4
45
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
46
Luliconazole Approved Phase 2, Phase 3 187164-19-8
47
Econazole Approved Phase 2 27220-47-9 3198
48
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
49
Aminolevulinic acid Approved Phase 2 106-60-5 137
50
Posaconazole Approved, Investigational, Vet_approved Phase 2 171228-49-2 147912

Interventional clinical trials:

(show top 50) (show all 138)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
2 A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
3 Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
4 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
5 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
6 Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
7 A Prospective, Double-blind, Placebo-controlled Trial of Topical Penlac Nail Lacquer for Therapy of Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
8 A Multicenter, Open Label, Single-arm Study Evaluating the Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis of the Toenails Completed NCT02812771 Phase 4 Efinaconazole
9 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Completed NCT03110029 Phase 4 Efinaconazole 10% Topical Application Solution [JUBLIA]
10 Change in SCIO (Scoring Clinical Index For Onychomycosis) in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
11 An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
12 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
13 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus a Fungal Nail Treatment Set Containing Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
14 Determination of Antifungal Activity of Loceryl Nail Lacquer 5% When Used Concomitantly With a Cosmetic Nail Varnish Compared to a Loceryl Nail Lacquer (NL) 5% Alone in Treatment of Toenail Distal Subungual Onychomycosis Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
15 An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
16 Comparison of the Efficacy and Safety Between Long-pulsed Nd:YAG, Amorolfine and Combination of Long-pulsed Nd:YAG and Amorolfine in Treating Non-dermatophyte and Mixed-infection Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
17 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
18 A Multicenter, Open-label, Non-controlled, Single-arm Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Active, not recruiting NCT03280927 Phase 4 Jublia®
19 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
20 Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Unknown status NCT02961634 Phase 3 Ciclopirox 8%
21 Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis Unknown status NCT03171584 Phase 3 Terbinafine
22 A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients With Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of TDT 067 for 48 Weeks Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
23 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Completed NCT02549001 Phase 3 P-3058 10%;vehicle of P-3058 10%;amorolfine 5%
24 Multicentre, Open Label Study to Assess the Tolerability of P-3058 Nail Solution in Paediatric Patients Affected by Mild-to-moderate Onychomycosis Completed NCT02547701 Phase 3 P-3058
25 Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01008033 Phase 3 IDP-108;Vehicle
26 The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01007708 Phase 3 IDP-108;Vehicle
27 Safety and Efficacy of Luliconazole Solution, 10% With Two Dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2B/3 Study Completed NCT01431820 Phase 2, Phase 3 Luliconazole Solution, 10%;Vehicle Solution
28 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo
29 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443820 Phase 3 terbinafine;Placebo;terbinafine;Placebo
30 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
31 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
32 A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
33 A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail. Completed NCT00356915 Phase 3 Itraconazole 100mg capsules;Itraconazole 200mg tablets;Placebo tablets
34 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Completed NCT03168841 Phase 3 Efinaconazole Topical
35 A Double-blind, Randomized, Multicenter, Placebo- Controlled Phase 3 Trial to Prove the Superiority of Bifonazole vs. Placebo After 4 Weeks of Onychomycosis Treatment/ as a Follow-up of a 2 Weeks Treatment of Non-surgical Nail Ablation of Diseased Nail Matrix With 40% Urea Paste Completed NCT00781820 Phase 3 Bifonazole cream 1%;Placebo cream
36 Multi-Center Trial: Evaluation of PinPointe FootLaser Treatment for Infected Toenails (Onychomycosis) Completed NCT00935649 Phase 2, Phase 3
37 A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
38 A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02859519 Phase 3 MOB015B;MOB015B Vehicle
39 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Wks Terminated NCT01208168 Phase 3 NAB001;Vehicle alone
40 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks Terminated NCT01208129 Phase 3 NAB001;Placebo control
41 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Withdrawn NCT03094468 Phase 3 P-3058 (terbinafine hydrochloride 10%);Vehicle of P-3058
42 Noveon Laser Treatment of Onychomycosis: A Device Performance Clinical Study Unknown status NCT00771732 Phase 2
43 The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study Unknown status NCT02644551 Phase 2 CELEXT07;Penlac
44 A Phase II Trial of the Safety, Local Tolerability, and Efficacy of EcoNail™ (Econazole 5%/SEPA® 18% Nail Lacquer) in Onychomycosis of the Great Toenail Unknown status NCT00385502 Phase 2 EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
45 AVALIAÇÃO DO USO DO LASER ERBIUM-DOPED YTTRIUM ALUMINIUM GARNET (Er:YAG) ASSOCIADO AO ESMALTE DE AMOROLFINA NO TRATAMENTO DA ONICOMICOSE Unknown status NCT01528813 Phase 2 Amorolfine lacquer
46 Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
47 A Pilot Study to Assess The Therapeutic Effectiveness Of Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis Unknown status NCT03471455 Phase 2 Isotretinoin;Terbinafine;Itraconazole 200 mg
48 An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) Completed NCT01814020 Phase 2 MOB015B
49 A Multi-center, Randomized, Double-blind, Vehicle-controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients Completed NCT03207906 Phase 2 VBP-926
50 An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis Completed NCT00680160 Phase 2 AN2690

Search NIH Clinical Center for Paronychia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ciclopirox
Ciclopirox olamine
Itraconazole
tavaborole
terbinafine
Terbinafine hydrochloride

Cochrane evidence based reviews: paronychia

Genetic Tests for Paronychia

Anatomical Context for Paronychia

MalaCards organs/tissues related to Paronychia:

40
Skin, Lung, Testes, Bone, Breast, Colon, T Cells

Publications for Paronychia

Articles related to Paronychia:

(show top 50) (show all 1006)
# Title Authors PMID Year
1
[Topical steroids in the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab]. 61 54
20417368 2010
2
Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. 54 61
20103661 2010
3
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. 61 54
19689244 2009
4
[Cutaneous toxicities]. 61 54
18931563 2008
5
Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. 61 54
17147969 2007
6
The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. 54 61
16965448 2006
7
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. 61 54
16844529 2006
8
Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. 54 61
16403122 2006
9
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. 54 61
16012181 2005
10
Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. 61 54
14571080 2003
11
Chronic paronychia with subungual purpura. 61
30829296 2020
12
Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. 61
32517152 2020
13
Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects. 61
32533336 2020
14
Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601). 61
32559335 2020
15
First- and third- generation EGFR inhibitors mediate distinct phosphoprotein signalling networks: implications for adverse dermatologic reactions. 61
32479649 2020
16
Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and need for multiple medical and procedural therapies. 61
32526318 2020
17
Clinical Significance of Candida Isolation from Dystrophic Fingernails. 61
32563206 2020
18
Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study. 61
32501998 2020
19
Acute Paronychia and Reactive Capillary Proliferation in a Patient on Erlotinib. 61
32565575 2020
20
Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. 61
32159882 2020
21
Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial. 61
32407455 2020
22
Pemphigus vegetans with paronychia-like changes resistant to rituximab therapy. 61
32367637 2020
23
Nail Changes Induced by Chemotherapeutic Agents. 61
32565559 2020
24
Management of Paronychia in Patients With Apert Syndrome. 61
32398550 2020
25
Metastatic Osteoarticular Infective Endocarditis by Methicillin-sensitive Staphylococcus Aureus. 61
32542174 2020
26
Selumetinib in Children with Inoperable Plexiform Neurofibromas. 61
32187457 2020
27
Carpal tunnel syndrome and associated nail changes: Review and examples from the author's practice. 61
32199899 2020
28
Cutaneous leishmaniasis: A great imitator. 61
32513395 2020
29
Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study. 61
31763692 2020
30
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab. 61
31641845 2020
31
Phytochemicals, Antioxidant Activity and Ethnobotanical Uses of Balanites aegyptiaca (L.) Del. Fruits from the Arid Zone of Mauritania, Northwest Africa. 61
32213817 2020
32
[Chronic paronychia and Candida: A descriptive and analytical study of 164 cases]. 61
31839272 2020
33
Skin Infections and Outpatient Burn Management: Skin Infections in Patients With Diabetes. 61
31995351 2020
34
Paronychia argentea Lam. protects renal endothelial cells against oxidative injury. 61
31629861 2020
35
Mental disorder or conscious disturbance in epidermal growth factor receptor-tyrosine kinase inhibitor treatment of advanced lung adenocarcinoma. 61
32256269 2020
36
Topical and device-based treatments for fungal infections of the toenails. 61
31978269 2020
37
Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report. 61
32021859 2020
38
A Rare Case of Extensive Pemphigus Vegetans. 61
32055517 2020
39
The Dark Side of Gefitinib: Reflectance Confocal Microscopy Applied to Hair Hyperpigmentation. 61
32021862 2020
40
Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. 61
30832554 2020
41
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. 61
31345012 2020
42
Recalcitrant trametinib-induced paronychia treated successfully with topical timolol in a pediatric patient. 61
31705590 2020
43
EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy. 61
31974771 2020
44
The treatment of onychogryphosis of hand nails by total matricectomy and dorsal V-Y advancement flap. 61
32160492 2020
45
A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia. 61
31240513 2019
46
A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy. 61
31397829 2019
47
Nail apparatus squamous cell carcinoma mimicking paronychia. 61
31502299 2019
48
Ungual Tuberculosis: A Unique Clinical Case. 61
31799269 2019
49
Group A Streptococcal Paronychia and Blistering Distal Dactylitis in Children: Diagnostic Accuracy of a Rapid Diagnostic Test and Efficacy of Antibiotic Treatment. 61
31782958 2019
50
Scanning Electron Microscopy of Erlotinib-induced Hair Changes: Pili Torti et Canaliculi. 61
32030058 2019

Variations for Paronychia

Expression for Paronychia

Search GEO for disease gene expression data for Paronychia.

Pathways for Paronychia

Pathways related to Paronychia according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 WNK1 MTOR MAP3K8 MAP2K7 KRAS HRAS
2
Show member pathways
13.71 MTOR MAP2K7 KRAS HRAS ERBB4 ERBB3
3
Show member pathways
13.69 MAP2K7 KRAS HRAS ERBB4 ERBB3 ERBB2
4
Show member pathways
13.67 MTOR MAP2K7 KRAS HRAS ERBB4 ERBB3
5
Show member pathways
13.55 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
6
Show member pathways
13.55 MTOR MAP3K8 MAP2K7 KRAS HRAS ERBB4
7
Show member pathways
13.46 MTOR MAP3K8 KRAS HRAS ERBB4 ERBB3
8
Show member pathways
13.42 WNK1 MTOR MAP3K8 KRAS HRAS ERBB4
9
Show member pathways
13.37 MAP3K8 KRAS HRAS ERBB4 ERBB3 ERBB2
10
Show member pathways
13.32 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
11
Show member pathways
13.28 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
12
Show member pathways
13.23 MTOR MAP3K8 MAP2K7 KRAS HRAS ERBB4
13
Show member pathways
13.08 MTOR MAP3K8 MAP2K7 KRAS HRAS EGFR
14
Show member pathways
13.05 MAP3K8 MAP2K7 KRAS HRAS EGFR
15
Show member pathways
13.03 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
16
Show member pathways
12.94 MTOR MAP2K7 KRAS HRAS EGFR
17
Show member pathways
12.93 MTOR KRAS HRAS ERBB3 ERBB2 EGFR
18
Show member pathways
12.91 MAP2K7 KRAS HRAS ERBB2 EGFR
19
Show member pathways
12.88 MTOR KRAS HRAS ERBB2 EGFR
20 12.85 MTOR KRAS HRAS ERBB2 EGFR
21
Show member pathways
12.78 MTOR KRAS HRAS ERBB2 EGFR
22
Show member pathways
12.77 MTOR MAP2K7 KRAS HRAS ERBB3 ERBB2
23
Show member pathways
12.77 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
24 12.73 MAP3K8 MAP2K7 KRAS HRAS ERBB4 ERBB3
25
Show member pathways
12.7 MTOR MAP2K7 KRAS HRAS EGFR
26
Show member pathways
12.7 MTOR MAP2K7 KRAS HRAS ERBB3 ERBB2
27
Show member pathways
12.69 MAP3K8 MAP2K7 KRAS HRAS EGFR
28
Show member pathways
12.68 MTOR MAP2K7 KRAS HRAS EGFR
29
Show member pathways
12.66 MTOR MAP3K8 MAP2K7 KRAS HRAS EGFR
30
Show member pathways
12.65 MTOR MAP3K8 MAP2K7 KRAS HRAS ERBB4
31
Show member pathways
12.59 KRAS HRAS ERBB2 EGFR
32 12.59 MTOR KRAS HRAS ERBB3 ERBB2 EGFR
33
Show member pathways
12.54 MTOR MAP2K7 KRAS HRAS EGFR
34
Show member pathways
12.54 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
35
Show member pathways
12.53 MTOR MAP3K8 MAP2K7 HRAS
36
Show member pathways
12.53 MTOR MAP2K7 KRAS HRAS ERBB4 ERBB3
37
Show member pathways
12.5 MTOR KRAS HRAS ERBB2
38
Show member pathways
12.47 MTOR MAP2K7 KRAS HRAS
39
Show member pathways
12.46 MTOR KRAS HRAS EGFR
40
Show member pathways
12.44 MTOR MAP2K7 KRAS HRAS
41
Show member pathways
12.44 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
42
Show member pathways
12.43 MAP2K7 KRAS HRAS EGFR
43
Show member pathways
12.43 MTOR KRAS HRAS EGFR
44
Show member pathways
12.41 MTOR MAP2K7 KRAS HRAS ERBB4 ERBB3
45
Show member pathways
12.36 MTOR MAP2K7 KRAS HRAS EGFR
46
Show member pathways
12.36 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
47
Show member pathways
12.35 HRAS ERBB3 ERBB2 EGFR
48
Show member pathways
12.34 MTOR HRAS ERBB2 EGFR
49
Show member pathways
12.32 ERBB4 ERBB3 ERBB2 EGFR
50 12.26 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2

GO Terms for Paronychia

Cellular components related to Paronychia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.06 WNK1 OLAH MTOR MAP3K8 MAP2K7 KRAS
2 receptor complex GO:0043235 9.56 ERBB4 ERBB3 ERBB2 EGFR
3 basolateral plasma membrane GO:0016323 9.46 ERBB4 ERBB3 ERBB2 EGFR
4 ERBB3:ERBB2 complex GO:0038143 8.96 ERBB3 ERBB2
5 basal plasma membrane GO:0009925 8.92 ERBB4 ERBB3 ERBB2 EGFR

Biological processes related to Paronychia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.17 MAP3K8 MAP2K7 KRAS HRAS ERBB4 ERBB3
2 positive regulation of cell proliferation GO:0008284 10 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
3 positive regulation of gene expression GO:0010628 9.97 MTOR KRAS HRAS ERBB3 ERBB2
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 MAP2K7 HRAS ERBB4 EGFR
5 positive regulation of protein kinase B signaling GO:0051897 9.85 MTOR ERBB4 ERBB3 ERBB2 EGFR
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.84 ERBB4 ERBB3 ERBB2 EGFR
7 peptidyl-tyrosine phosphorylation GO:0018108 9.83 MAP2K7 ERBB4 ERBB3 ERBB2 EGFR
8 wound healing GO:0042060 9.81 MTOR ERBB3 ERBB2 EGFR
9 positive regulation of kinase activity GO:0033674 9.8 ERBB4 ERBB3 ERBB2 EGFR
10 positive regulation of protein phosphorylation GO:0001934 9.8 MTOR KRAS HRAS ERBB4 ERBB2 EGFR
11 activation of protein kinase activity GO:0032147 9.79 WNK1 MAP3K8 MAP2K7
12 liver development GO:0001889 9.78 KRAS HRAS EGFR
13 positive regulation of MAP kinase activity GO:0043406 9.78 KRAS HRAS ERBB2 EGFR
14 positive regulation of epithelial cell proliferation GO:0050679 9.77 HRAS ERBB2 EGFR
15 protein autophosphorylation GO:0046777 9.73 WNK1 MTOR ERBB4 ERBB2 EGFR AURKA
16 cellular response to epidermal growth factor stimulus GO:0071364 9.72 ERBB4 ERBB2 EGFR
17 regulation of cell motility GO:2000145 9.71 ERBB4 ERBB3 ERBB2 EGFR
18 MAPK cascade GO:0000165 9.7 MAP3K8 KRAS HRAS ERBB4 ERBB3 ERBB2
19 ERBB2 signaling pathway GO:0038128 9.67 ERBB4 ERBB3 ERBB2 EGFR
20 regulation of long-term neuronal synaptic plasticity GO:0048169 9.62 KRAS HRAS
21 response to osmotic stress GO:0006970 9.62 MAP2K7 EGFR
22 phosphorylation GO:0016310 9.61 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3
23 response to isolation stress GO:0035900 9.6 KRAS HRAS
24 negative regulation of ERBB signaling pathway GO:1901185 9.56 ERBB2 EGFR
25 protein phosphorylation GO:0006468 9.28 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3

Molecular functions related to Paronychia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 10.06 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3
2 ATP binding GO:0005524 9.97 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3
3 nucleotide binding GO:0000166 9.9 WNK1 MTOR MAP3K8 MAP2K7 KRAS HRAS
4 protein kinase binding GO:0019901 9.88 WNK1 MTOR MAP2K7 EGFR AURKA
5 protein serine/threonine kinase activity GO:0004674 9.83 WNK1 MTOR MAP3K8 MAP2K7 AURKA
6 protein-containing complex binding GO:0044877 9.81 MTOR KRAS HRAS EGFR
7 protein phosphatase binding GO:0019903 9.67 MAP2K7 ERBB2 EGFR
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.67 ERBB4 ERBB3 ERBB2 EGFR
9 protein tyrosine kinase activity GO:0004713 9.65 MAP2K7 ERBB4 ERBB3 ERBB2 EGFR
10 kinase activity GO:0016301 9.61 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3
11 ErbB-3 class receptor binding GO:0043125 9.46 ERBB3 ERBB2
12 protein kinase activity GO:0004672 9.28 WNK1 MTOR MAP3K8 MAP2K7 ERBB4 ERBB3

Sources for Paronychia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....